Skip to main content

Advertisement

Table 1 Clinicopathologic factors of breast cancer patients in disease-free and progressed statuses.

From: Cumulative receiver operating characteristics for analyzing interaction between tissue visfatin and clinicopathologic factors in breast cancer progression

Factors Disease-free (n = 84) Progresseda (n = 21) P
n % n %
Tissue visfatin < 0.001
 ≤ 50% 51 60.7 4 19.0  
 > 50% 33 39.3 17 81.0  
Stage < 0.001
 I, II 73 86.9 10 47.6  
 III, IV 11 13.1 11 52.4  
Grade 0.669
 1, 2 60 71.4 14 66.7  
 3 24 28.6 7 33.3  
Age (years) 0.002
 < 50  51 60.7 5 23.8  
 ≥ 50 33 39.3 16 76.2  
BMI (kg/m2) 0.195
 < 24 53 63.1 10 47.6  
 ≥ 24 31 36.9 11 52.4  
Tumor size (cm) 0.007
 < 2 44 52.4 4 19.0  
 ≥ 2 40 47.6 17 81.0  
LN metastasis < 0.001
 Negative 59 70.2 6 28.6  
 Positive 25 29.8 15 71.4  
ER 0.051
 Positive 59 70.2 10 47.6  
 Negative 25 29.8 11 52.4  
PR 0.139
 Positive 51 60.7 9 42.9  
 Negative 33 39.3 12 57.1  
HER2 status 0.417
 Positive 32 38.1 6 28.6  
 Negative 52 61.9 15 71.4  
Triple negative 0.031
 No 70 83.3 13 61.9  
 Yes 14 16.7 8 38.1  
RT 0.487
 Yes 51 60.7 11 52.4  
 No 33 39.3 10 47.6  
CT 0.557
 Yes 66 78.6 18 85.7  
 No 18 21.4 3 14.3  
HT < 0.001
 Yes 60 71.4 6 28.6  
 No 24 28.6 15 71.4  
  1. BMI body mass index, LN lymph node, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, RT radiotherapy, CT chemotherapy, HT hormone therapy
  2. aProgressed patients including patients with breast cancer recurrence or patients expired during 5-year follow-up